Skip to content

Study · Randomized controlled trial · n = 52 · 2015

5 results

A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis.

Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Scott EM, Naismith SL, Moore L, Alvares GA, Redoblado Hodge MA, Guastella AJ

Schizophrenia bulletin23 Jun 2014Cited by 97 (Europe PMC)

PMID24962607 (opens in a new tab)PMCIDPMC4332939 (opens in a new tab)DOI10.1093/schbul/sbu094 (opens in a new tab)PepBankPUB-24962607
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In young people with early psychosis, oxytocin nasal spray with social cognition training gave no benefit over placebo on social cognition, a primary outcome.

    In plain wordsIn young people with early psychosis, oxytocin spray did not improve social cognition more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSocial cognition (Reading the Mind in the Eyes Test)
    Study

    n = 52

    Comparator
    Placebo nasal spray plus social cognition training
    Analysis
    Primary
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    24 IU twice daily, plus an additional dose before each weekly session · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Results showed that on all primary and secondary outcomes, there was no benefit of oxytocin nasal spray treatment in comparison to placebo.
    2 context sentences
    Summary · context
    Primary outcomes included the Reading the Mind in the Eyes Test, the Scale for the Assessment of Positive and Negative Symptoms, and the Social Functioning Scale.
    Summary · context
    Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In young people with early psychosis, oxytocin nasal spray with social cognition training gave no benefit over placebo on clinical symptoms, a primary outcome.

    In plain wordsIn young people with early psychosis, oxytocin spray did not reduce symptoms more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSymptoms (Scale for the Assessment of Positive and Negative Symptoms)
    Study

    n = 52

    Comparator
    Placebo nasal spray plus social cognition training
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24 IU twice daily, plus an additional dose before each weekly session · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Results showed that on all primary and secondary outcomes, there was no benefit of oxytocin nasal spray treatment in comparison to placebo.
    2 context sentences
    Summary · context
    Primary outcomes included the Reading the Mind in the Eyes Test, the Scale for the Assessment of Positive and Negative Symptoms, and the Social Functioning Scale.
    Summary · context
    Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In young people with early psychosis, oxytocin nasal spray with social cognition training gave no benefit over placebo on social functioning, a primary outcome.

    In plain wordsIn young people with early psychosis, oxytocin spray did not improve social functioning more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSocial functioning (Social Functioning Scale)
    Study

    n = 52

    Comparator
    Placebo nasal spray plus social cognition training
    Analysis
    Primary
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24 IU twice daily, plus an additional dose before each weekly session · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Results showed that on all primary and secondary outcomes, there was no benefit of oxytocin nasal spray treatment in comparison to placebo.
    2 context sentences
    Summary · context
    Primary outcomes included the Reading the Mind in the Eyes Test, the Scale for the Assessment of Positive and Negative Symptoms, and the Social Functioning Scale.
    Summary · context
    Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In young people with early psychosis, oxytocin nasal spray with social cognition training gave no benefit over placebo on all secondary outcomes.

    In plain wordsIn young people with early psychosis, oxytocin spray did not beat placebo on any secondary measure.

    Peptide
    Oxytocin
    Outcome
    No significant changeSecondary outcomes (social cognition, symptom severity, social functioning)
    Study

    n = 52

    Comparator
    Placebo nasal spray plus social cognition training
    Analysis
    Secondary
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    24 IU twice daily, plus an additional dose before each weekly session · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Results showed that on all primary and secondary outcomes, there was no benefit of oxytocin nasal spray treatment in comparison to placebo.
    2 context sentences
    Summary · context
    Secondary outcomes included self-report and behavioral assessments of social cognition, symptom severity, and social functioning.
    Summary · context
    Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In young people with early psychosis, an exploratory post hoc analysis linked more nasal spray use to reduced negative symptoms in the oxytocin condition only.

    In plain wordsIn young people with early psychosis, more spray use was linked to fewer negative symptoms in the oxytocin group only; this was an exploratory analysis.

    Peptide
    Oxytocin
    Outcome
    DecreaseNegative symptoms by nasal spray use
    Study

    n = 52

    Comparator
    Placebo group
    Analysis
    Exploratory
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24 IU twice daily, plus an additional dose before each weekly session · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Exploratory post hoc analysis suggested that increased use of nasal spray was, however, associated with reductions in negative symptoms in the oxytocin condition only.
    2 context sentences
    Summary · context
    In a double-blind, randomized, placebo-controlled, between-subjects trial, 52 individuals (aged 16-35 years) diagnosed with an early psychosis schizophrenia-spectrum illness were recruited.
    Summary · context
    Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.